GlassScriptPhysician profile
Christopher J Jacquinot
NPI 1003016361
$3,918.79
in general payments reported to CMS, 2019-2025
19 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $368 · 2021: $360 · 2022: $486 · 2023: $475 · 2024: $365 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $466.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $583.19 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $579.35 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $452.36 | 2019-2025 | Tryptyr, Precision7, Rocklatan |
| Sight Sciences, INC. | $390.70 | 2019-2025 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $362.35 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $315.13 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $247.25 | 2019-2025 | Cequa |
| Abbvie INC. | $186.77 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $182.58 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $143.18 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Osmotica Pharmaceutical Corp. | $136.31 | 2019 | |
| Dompe US, INC. | $125.11 | 2023-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $75.85 | 2021-2022 | |
| Allergan, INC. | $54.20 | 2019 | |
| Shire North American Group INC | $22.29 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $19.44 | 2025 | Tyrvaya |
| Glaukos Corporation | $19.39 | 2024 | Radius |
| Maculogix, INC. | $13.98 | 2019 | |
| Abb Con-Cise Optical Group LLC | $9.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jacquinot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.